Hello all,

Below is what Joanne Katz sent me late last night. That is why I posted it. I thought it was the actual presentation.

"It was already on Friday:



A. Beta-Amyloid Diseases
06r. Imaging & Biomarkers: other

Date: Friday 20th - Posters

---

PARKINSON’S DISEASE BIOMARKER DISCOVERY USING SOMASCAN PROTEOMIC TECHNOLOGY

155


J. Ash, United Kingdom





IDENTIFICATION OF SYNAPTIC PROTEINS DETECTABLE IN THE CEREBROSPINAL FLUID IN THE SEARCH FOR BIOMARKERS OF PRECLINICAL ALZHEIMER'S DISEASE

156


O. Belbin, Spain





DEVELOPMENT OF NEW MASS SPECTROMETRY BASED ASSAYS FOR ANALYSIS OF HUMAN CEREBROSPINAL FLUID

157


G. Brinkmalm, Sweden





RATIONAL DESIGN OF ENVIRONMENT SENSITIVE FLUOROPHORES FOR DETECTION OF AGGREGATED AMYOID PROTEIN BIOMARKERS IN NEUROLOGICAL DISEASES

158


K. Cao, USA





BINDING IN VISUAL WORKING MEMORY: A COGNITIVE BIOMARKER FOR EARLY ALZHEIMER'S DISEASE?

160


M. Heider, Germany





SEARCHING FOR A MOLECULAR SIGNATURE OF ALZHEIMER'S DISEASE IN DOWN SYNDROME PLASMA

161


M.F. Iulita, Canada





PLASMA CHOLINE ACETYLTRANSFERASE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND AD

162


A. Karami, Sweden





THE LYMPRO® ASSAY: A BIOMARKER FOR ALZHEIMER’S DISEASE USING BLOOD SAMPLES FROM CLINICALLY DIAGNOSED ALZHEIMER’S DISEASE AND COGNITIVELY INTACT SUBJECTS

163


L. Kirby, USA





PLASMA AND CSF PROTEINS JOINTLY PREDICT MID-TERM PROGRESSION FROM MCI TO AD

164


B. Lehallier, USA





PREPARATION AND STABILITY TESTING OF A QUALITY CONTROL MATERIAL FOR NEUROCHEMICAL DEMENTIA DIAGNOSTICS ASSAYS

165


P. Lewczuk, Germany





AMYLOID BETA 42/40 CSF CONCENTRATION RATIO WITH TWO NOVEL ASSAYS FOR AN EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE

166


P. Lewczuk, Germany





CYP2D6 GENE AND PLASMA CONCENTRATION OF S-DONEPEZIL AS BIOMARKERS TO PREDICT AND EVALUATE CLINICAL OUTCOME OF DONEPEZIL IN CHINESE ALZHEIMER’S DISEASE PATIENTS

167


J. Lu, China





DECREASED LEVELS OF CGMP IN CSF ARE ASSOCIATED WITH COGNITIVE DECLINE AND AMYLOID PATHOLOGY IN ALZHEIMER’S DISEASE

168


C. Mar, Spain





HIPPOCAMPAL SUBFIELDS REPRODUCIBILITY: A EUROPEAN MULTI-SITE 3T STUDY

169


M. Marizzoni, Italy





A NOVEL IMMUNOASSAY FOR LONGITUDINAL MEASUREMENTS OF AMYLOID-BETA OLIGOMERS IN HUMAN CSF WITH POTENTIAL TO ASSESS THERAPEUTIC RESPONSE TO IMMUNOTHERAPY

170


M. Matijevic, USA





AUTOMATION OF COMMERCIAL AMYLOID-BETA AND TAU ELISAS WILL LOWER INTER-LAB VARIABILITY

171


A. Matzen, Germany





CSF BIOMARKER VARIABILITY IN THE ALZHEIMER´S ASSOCIATION QUALITY CONTROL PROGRAM

172


S. Persson, Sweden





EVALUATION OF RETINAL CHANGES IN MILD COGNITIVE IMPAIRMENT, ALZHEIMER DEMENTIA, NON-ALZHEIMER DEMENTIA AND PD

173


J. Pillai, USA





CHANGES OF PLASMA AMYLOID BETA 40/42 RATIOS IN KOREAN SPORADIC EARLY-ONSET ALZHEIMER'S DISEASE PATIENTS

174


P. Sun Ah, Korea





RED BLOOD CELL FATTY ACIDS ARE SIGNIFICANTLY ALTERED IN SOUTH AUSTRALIAN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE COMPARED TO CONTROLS

175


P. Thomas, Australia





IMPACT OF FREQUENT CSF SAMPLING ON CSF ABETA LEVELS: SYSTEMATIC APPROACH TO ELUCIDATE INFLUENCING FACTORS

176


B. Van Broeck, Belgium





SPEECH DISORDERS IN ALZHEIMER´S DISEASE

177


P. Walecki, Poland





GLYCOSYLATION OF HUMAN PLASMA CLUSTERIN PROVIDES NOVEL BIOMARKERS OF ALZHEIMER’S DISEASE

178


M. Ward, United Kingdom





PLASMA IL-6 AND TRAIL IDENTIFIED AS BIOMARKERS OF ALZHEIMER'S DISEASE

179


Y. Wu, Taiwan









Kind regards,

Joanne Katz
Project Coordinator
kenes-international
Tel: +41 22 9080488 Ext 920
Fax: +41 22 9069140
Email: jkatz@kenes.com
Site: www.kenes.com "

Manolo